Phase 3 Study of Oral Ibrexafungerp (SCY-078) Vs. Placebo in Subjects With Recurrent Vulvovaginal Candidiasis (VVC)
Trial details
- Registry ID
- NCT04029116
- Phase
- Phase 3
Drug identity checked against registry records
Also recorded as SCY-078
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Phase 3 Study of Oral Ibrexafungerp (SCY-078) Vs. Placebo in Subjects With Recurrent Vulvovaginal Candidiasis (VVC)NCT04029116 | SCYX | Phase 3 | Completed | 2021-09-01Actual |
| No regulatory events match this view.This does not mean no FDA events have occurred. |